Constellation Pharmaceuticals Announces Appointment to Board of Directors
20. Februar 2019 07:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs
03. Januar 2019 07:00 ET
|
Constellation Pharmaceuticals , Inc.
Constellation CEO Jigar Raythatha will present at the J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019, at 4PM PST/7PM ESTThe presentation will include updated results from the first...
Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
20. Dezember 2018 13:34 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
10. Dezember 2018 16:49 ET
|
Constellation Pharmaceuticals , Inc.
Dosing has begun in a randomized study of CPI-1205 / enzalutamide combination versus enzalutamide alone in second-line mCRPCSingle-arm CPI-1205 / abiraterone / prednisone combination added to...
Constellation Pharmaceuticals to Present at BMO Healthcare Conference
29. November 2018 14:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Appoints Patrick Trojer, Ph.D., as Chief Scientific Officer
29. November 2018 09:22 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (the “Company”) (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics...
Constellation Pharmaceuticals Highlights EZH2 Inhibition Program in Prostate Cancer at Biomedical Conference
15. November 2018 07:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2018 Financial Results
08. November 2018 16:30 ET
|
Constellation Pharmaceuticals , Inc.
Company Executing on Lead Programs CPI-1205 and CPI-0610Expects to Evaluate Proof of Concept for Both Programs in Mid-2019 CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Constellation...
Constellation Pharmaceuticals to Present at Upcoming Investor Conferences
02. November 2018 13:08 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Receives FDA Fast Track Designation for CPI-0610 in Treatment of Myelofibrosis
01. November 2018 07:00 ET
|
Constellation Pharmaceuticals , Inc.
- Recently Expanded and Enhanced MANIFEST Phase 2 Trial Ongoing with Proof of Concept Data Expected Mid-2019 CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals,...